作者: P A Bunn , J Crowley , K Kelly , M B Hazuka , K Beasley
DOI: 10.1200/JCO.1995.13.7.1632
关键词:
摘要: PURPOSEThis phase III randomized trial was designed to determine if granulocyte-macrophage colony-stimulating factor (GM-CSF) reduces the hematologic toxicity and morbidity induced by chemoradiotherapy in limited-stage small-cell lung cancer (SCLC).METHODSThis multicenter prospective 230 patients receive chemotherapy radiotherapy (RT) with or without GM-CSF given on days 4 18 of each six cycles. The primary end point toxicity. Secondary points included following: nonhematologic toxicities; (1) fever, (2) antibiotics, (3) hospitalization, (4) infection; number transfusions; drug doses delivered; response rates survival.RESULTSThere a statistically significant increase frequency duration life-threatening thrombocytopenia (P < .001) GM-CSF. had significantly more toxic deaths .01), toxicities, hospital, higher incidence intravenous...